Wegovy and Ozempic are the same drug, semaglutide, made by the same company (Novo Nordisk) and delivered the same way: a once-weekly injection under the skin. The difference is what they’re approved to treat and how much you take. Ozempic is prescribed for type 2 diabetes, while Wegovy is prescribed for weight management, heart disease risk reduction, and a form of fatty liver disease called MASH.
Same Molecule, Different Purpose
Semaglutide is 94% structurally identical to a hormone your body already makes called GLP-1. This hormone kicks in after you eat, telling your pancreas to release insulin and signaling your brain that you’re full. Semaglutide mimics that process, but it lasts far longer in your body than the natural hormone does, which is why a single weekly injection works.
Beyond insulin, semaglutide slows how fast food leaves your stomach, reduces the release of a hormone that raises blood sugar (glucagon), and interacts with appetite centers in the brain. That combination lowers blood sugar and reduces hunger, which is why the same molecule works for both diabetes and weight loss. The FDA simply approved it under two brand names for two different patient populations.
How the Doses Compare
The most important practical difference is dosing. Both medications start at 0.25 mg per week and increase gradually every four weeks, but they top out at very different levels.
- Ozempic maxes out at 2.0 mg per week. It’s dosed to control blood sugar in people with type 2 diabetes.
- Wegovy can go up to 2.4 mg per week for most indications, and the newer Wegovy HD pen goes as high as 7.2 mg per week for weight management.
The gradual ramp-up schedule exists for a reason. Starting at a low dose and increasing over several months gives your digestive system time to adjust and reduces the chance of severe nausea or vomiting.
Weight Loss at Different Doses
Because Wegovy is prescribed at higher doses, it produces more weight loss. In a head-to-head comparison among people with type 2 diabetes and overweight, the 2.4 mg dose (Wegovy’s standard maintenance dose) led to 9.6% body weight loss over 68 weeks, compared to 7.0% with the 1.0 mg dose (a common Ozempic dose) and 3.4% with a placebo. That gap of roughly 2.5 percentage points may sound modest, but on a 220-pound person it translates to about 5 or 6 extra pounds lost.
People without type 2 diabetes typically lose a higher percentage of body weight on semaglutide than people with diabetes do, so the results in a general weight-loss population tend to be even more pronounced.
FDA-Approved Uses
Ozempic is approved specifically for type 2 diabetes management and for lowering the risk of heart attack, stroke, and kidney disease progression in people with type 2 diabetes. It is not FDA-approved for weight loss, even though doctors sometimes prescribe it off-label for that purpose.
Wegovy has a broader set of approvals. It’s indicated for weight management in adults and children 12 and older with obesity (or overweight with at least one weight-related health condition). In 2024, the FDA also approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults who have established heart disease along with obesity or overweight. More recently, it gained approval for treating a specific form of fatty liver disease (noncirrhotic MASH with moderate to advanced scarring).
Heart Health Benefits
Wegovy is the first weight-loss medication the FDA has approved specifically to lower serious cardiovascular risk. The approval was based on a large trial showing that adults with heart disease and obesity or overweight who took Wegovy had a meaningful reduction in heart attacks, strokes, and cardiovascular deaths compared to those on placebo. Ozempic has cardiovascular benefit data too, but its label ties those benefits to the type 2 diabetes population rather than to obesity or overweight on its own.
Side Effects Are Dose-Dependent
Because both drugs are semaglutide, the side effect profile is essentially the same. Gastrointestinal symptoms are the most common issue: nausea, diarrhea, vomiting, and constipation. These are a class effect of GLP-1 drugs and tend to peak during dose increases, then fade over time. Most cases are mild to moderate.
At the 2.4 mg Wegovy dose, about 44% of people experienced nausea, 30% had diarrhea, and roughly 25% reported vomiting or constipation. At the 1.0 mg Ozempic dose, digestive side effects were slightly less common (about 58% experienced any GI symptom versus 64% at the higher dose). Despite those numbers, very few people in either group stopped treatment because of side effects: around 3.5% at the lower dose and 4.2% at the higher dose.
The takeaway is that higher doses come with somewhat more digestive discomfort, but the difference between doses is smaller than you might expect given that the 2.4 mg dose is more than double the 1.0 mg dose.
Pen Design and Practical Use
There’s a small hardware difference worth knowing about. Ozempic comes as a multi-use pen, meaning a single pen contains several doses and you dial up the correct amount each week. Wegovy comes as a single-use, prefilled pen for each injection, so there’s no dialing involved. Some people find single-use pens simpler because there’s less room for dosing errors. Others prefer the multi-use pen because it means fewer devices to keep track of.
Both are injected subcutaneously, typically in the abdomen, thigh, or upper arm. Both are taken once a week on the same day each week.
Insurance and Cost Considerations
This is where the distinction between the two brands matters most in daily life. Insurance coverage depends heavily on which condition you’re being treated for. Ozempic is generally covered under diabetes benefits, so if you have a type 2 diabetes diagnosis, your plan is more likely to approve it. Wegovy coverage varies widely. Some insurers cover it for weight management, others only for cardiovascular indications or MASH, and some exclude it entirely.
Coverage policies are also shifting. California’s Medicaid program (Medi-Cal), for example, will stop covering both Ozempic and Wegovy for weight-loss indications starting in 2026, though it will still review non-weight-loss uses like cardiovascular risk and MASH on a case-by-case basis. Private insurers each set their own rules, so checking your specific plan’s formulary is essential before assuming either drug will be covered.
Without insurance, both medications carry a high list price, often exceeding $1,000 per month. Manufacturer savings programs exist but typically apply only if you have commercial insurance, not Medicare or Medicaid.
Which One Gets Prescribed
Your diagnosis largely determines which brand you’ll receive. If you have type 2 diabetes, you’ll typically be prescribed Ozempic. If your primary goal is weight management or cardiovascular risk reduction related to obesity, Wegovy is the intended product. Some people with type 2 diabetes who also need significant weight loss may be switched from Ozempic to Wegovy, though this depends on insurance approval and clinical judgment.
Because the active ingredient is identical, switching between the two is medically straightforward. The adjustment is mainly in dose and, sometimes, navigating a new prior authorization with your insurer.